[go: up one dir, main page]

EP3596224A1 - Procédé de détermination de la présence d'acide hyaluronique - Google Patents

Procédé de détermination de la présence d'acide hyaluronique

Info

Publication number
EP3596224A1
EP3596224A1 EP18722381.3A EP18722381A EP3596224A1 EP 3596224 A1 EP3596224 A1 EP 3596224A1 EP 18722381 A EP18722381 A EP 18722381A EP 3596224 A1 EP3596224 A1 EP 3596224A1
Authority
EP
European Patent Office
Prior art keywords
sample
solution
hyaluronic acid
determination
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18722381.3A
Other languages
German (de)
English (en)
Inventor
Stanislav PEPELIAEV
Radka HRUDIKOVA
Jana JILKOVA
Jaroslav PAVLIK
Vladimir Velebny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contipro AS
Original Assignee
Contipro AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contipro AS filed Critical Contipro AS
Publication of EP3596224A1 publication Critical patent/EP3596224A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02001—Hyaluronate lyase (4.2.2.1)

Definitions

  • the invention relates to the method of determination of hyaluronic acid in complex samples by cleavage with SpnHyl enzyme followed by the reaction with 3-methyl-2- benzothiazolinonhydrazone (MBTH) to form a coloured product analysed by
  • glycosaminoglycans these can be separated by precipitation before the cleavage, e.g. with use of cetyltrimethylammoniumbromide (CTAB) in acetate buffer and salt medium.
  • CTAB cetyltrimethylammoniumbromide
  • high content of reducing sugars e.g. glucose
  • their influence can be further eliminated, after removing the glycosaminoglycans and before the cleavage, by precipitating hyaluronic acid from the formed supernatant and then redissolving this sediment in acetate buffer and performing the cleavage step.
  • Hyaluronic acid (hyaluronan, hyaluronate, HA) is a linear glycosaminoglycan consisting of alternating molecules of glucuronic acid and N-acetylglucosamine. It is one of the basic building materials of connective tissue thanks to its exceptional rheological and mechanical properties.
  • hyaluronic acid is widely used in pharmaceutical and cosmetics industry (Shimmura et al. 1995; Kogan et al. 2007); its production has been constantly increasing.
  • the concentration of hyaluronic acid in blood serves as a biological marker of physiological state of joints and the whole moving apparatus.
  • many methods of determination of hyaluronic acid concentration have been developed, differing in both their sensitivity and basic principles.
  • the methods of determination of HA can be divided into nanogram, microgram, and milligram scales. According to the principle, the methods of determination of HA can be divided into the following categories:
  • Gravimetric methods belong to the oldest and the least accurate methods, where HA is precipitated with alcohol, the precipitate is then dried and weighed. The processes of precipitation and drying are slow, which takes up to two days. The sensitivity of the method is low, usually hundreds of milligrams per litre, moreover, other polysaccharides can precipitate concurrently during the precipitation. Gravimetry is conventionally used in biotechnological production of HA, where the composition of the culture medium is known and constant, other polysaccharides are absent, and the analysis time does not play an important role.
  • Turbidimetric methods exploit the properties of the complexes of glycosaminoglycans and aliphatic ammonium salts comprising at least one long aliphatic chain (cetylpyridinium chloride - CPC, or cetyltrimetylammonium bromide - CTAB). Under certain conditions these complexes form very stable colloid solutions.
  • the content of HA in a sample can be determined according to the level of turbidity of the colloid solution of "HA - aliphatic ammonium salt" (Oueslati et al., 2014). This method has a great advantage of a very short time of analysis.
  • the first colorimetric methods for determination of HA were based on the methods for detection of specific monosaccharides, such as N-acetylglucosamin in Elson-Morgan method with the Reissig's modification (Elson&Morgan, 1933; Reissig et al., 1955), and D-glucuronic acid in Dische method
  • HA being the polysaccharide, must be depolymerized into monosaccharides prior the colour reaction. Depolymerization is performed by 80% sulfuric acid at 60 °C (Dische, 1947), or 2N-hydrochloric acid at 100 °C (Reissig et al., 1955). In some
  • HA is cleaved with a lyase from S. hyalurolyticus into 4, 5 -unsaturated oligosaccharides. These are subsequently oxidized with periodic acid to formylpyruvate that reacts with
  • HA thiobarbiturate.
  • the sensitivity of this method is comparable with the Elson-Morgan method, but it is more user friendly.
  • the drawbacks of the method are "slow" hyaluronan lyase and the use of highly toxic arsenic compounds.
  • Chromatographic methods use a direct detection of HA at 201 nm, or at 232 nm in case of unsaturated HA forms (Gassier et al., 1993; Alkrad et al., 2002; Ruckmani et al., 2013). In both cases HA can be determined in pure solutions only, whereas the sensitivity is slightly lower than in colorimetric methods. On the contrary, the chromatography has the advantage of determination of molecular weight of HA. That is the main reason why the
  • Spectrophotometry is considered to be a very accurate and sensitive tool. At the same time, spectrophotometry is relatively cheap and simple and thus is widely used in laboratories. In order to keep the affordable price while maintaining the high sensitivity, the spectrophotometric determination of HA must be based on the reaction forming an intensively coloured product that absorbs at longer wave lengths. There are many agents reacting with saccharides to form coloured products. Some of them have been used for determination of other polysaccharides, such as metyl-2-benzothiazolinonhydrazon (MBTH) which is characterized by a low interaction with salts, proteins, and nucleic acids (Moretti&Thorson, 2002).
  • MTH metyl-2-benzothiazolinonhydrazon
  • MBTH has been used primarily for the determination of aldehydes (Hauser&Cummins, 1964).
  • the analysed aldehyde condenses with MBTH, and then follows the conversion into formazan upon reaction with the diazonium salt which is generated in the reaction medium by oxidation of the excess reagent. (Scheme 1). That forms highly a coloured product with the highest absorbance at620 nm (blue colour).
  • HA of various molecular weight 24, 73, 211, 400, 549, 875, 1690, and 2049 kDa
  • MBTH Anthon-Barrett method protocol
  • Controlled degradation of HA leading to the formation of only one low molecular product solves simultaneously three problems.
  • HA completely degraded in less than 5 minutes.
  • the product of the first condensation of ⁇ 2 and MBTH is a yellow intermediate having the maximum absorbance at 390 nm.
  • this yellow product can be used for the detection without the necessity of a further reaction.
  • different amounts of HA cleaved in 200 were mixed with 200 ⁇ ⁇ of 1M NaOH and 600 ⁇ of 0.1 % (w/v) MBTH. Then the reaction mixture was heated at different temperatures from 60 to 95 °C. The samples were then cooled to room temperature and measured at 390 nm. It was found that the dependence of the absorbance on the concentration is not linear, the intensity of colouring is not stable during the time, and the sensitivity of the reaction is very low (extinction coefficient of 1100 mol "1 ). This experiment proved the necessity of the second reaction.
  • the measurement error was less than 1%.
  • the first reaction is performed at 75°C, for not less than 30 and not more than 50 minutes. Such conditions offer allowance of ⁇ 2°C and the sufficient time for the manipulation with the samples, which significantly improves the analysis repeatability and robustness.
  • sample containing HA is mixed with the same volume of lOOmM acetate buffer pH 6 with lOOmM of NaCl.
  • the resulting 400 ⁇ is divided into two equal parts of 200 ⁇ ,. One is marked as the “sample” (S), the other as the
  • the absorbance is measured at 654 nm. After subtracting the absorbance of the "background” from the absorbance of the "sample", the concentration of HA can be calculated based of the extinction coefficient.
  • the hyaluronan-based medical remedies and nutritional supplements for joint care and support usually contain high amounts of other glycosaminoglycans along with HA, the most often it is chondroitin sulfate (CS) (Table 1). Glycosaminoglycans have similar physical and chemical properties and play a similar role within the organism, especially in connective tissues. Therefore, the next step of investigation was to determine conditions of the SpnHyl- MBTH method which would be suitable for HA detection in the presence of high amounts of CS.of SpnHyl-MBTH
  • the HA-CTAB complex was soluble in 50 mM acetic buffer pH 6 at concentrations of Na 2 S0 higher than 76 mM, whereas CS- CTAB dissolves at concentrations higher than 700 mM of Na 2 S0 4 ..
  • the analysed sample is premixed with the same volume of 160mM Na 2 S0 4 in lOOmM acetate buffer of pH 6 (referred to as the "reagent A") - in this case 100 and 100 ⁇ .
  • the thus treated sample is then mixed with l%w/v CTAB in 80mM Na 2 S0 4 , 50mM acetate buffer of pH 6 (referred to as the "reagent B").
  • the hindering low-molecular-weight impurities such as reducing sugars could be removed by fractioning the glycosaminoglycans with the CTAB precipitation.
  • the CS is removed by precipitation as described above.
  • the object of the invention is a method of determination of hyaluronic acid in a sample comprising the following steps:
  • the solution of a sample is prepared by mixing with acetate buffer containing monovalent salt so that pH of the final solution is within the range of 5 to 7, the concentration of acetate buffer is within the range of lOmM to 1M, and the ionic strength of the mixture corresponds to the solutions of monovalent salts with the concentration between 10 mM and 1M,
  • an acidic solution of a ferric salt comprising citric acid and sulfamic acid is added to the mixture, the mixture is then cooled for 5 to 15 minutes to the room temperature,
  • the solution of MBTH in step c) also includes dithiotreitol (DTT) in the concentrations 2-20mM.
  • the monovalent salt in the step a) is preferably in the concentration 50 mM and is selected from the group comprising NaCl, KC1, CH 3 COONa, NaN0 3 , Na 2 S0 4 , and K 2 S0 4 .
  • 1M aqueous solution of NaOH, KOH, or LiOH is preferably added as an alkali, wherein its final concentration in the reaction mixture is 0.25M.
  • step d 50mM aqueous solution of FeCl 3 , 0.2M aqueous solution of citric acid, and l%w/v aqueous solution of sulfamic acid are added in step d).
  • the step a) comprises a set of the following sub-steps:
  • the sample is mixed with acetate buffer and aqueous solution of Na 2 S0 4 or K 2 S0 4 so that the final concentration of acetate buffer after mixing is in range of lOmM to lOOmM and the concentration of the sulfate is between 75 and 300mM,
  • a2) 0.5-2%w/v aqueous solution of cetyltrimethylammoniumbromide or cetylpyridiniumchloride, comprising the same concentrations of acetate and sulfate as the sample after mixing in step al), is added to the sample solution from step al) in order to precipitate anionic glycosaminoglycans with a negative charge higher than HA, which lead to the sediment formation,
  • step a3) the sediment formed in step a2) is removed.
  • Na 2 S0 4 is added in steps al) and a2) so that its final concentration in the sample solution after mixing is 80mM, and acetate buffer is added so that its concentration in the sample solution after mixing is 50mM and pH is 6, and then the sediment is removed by centrifugation in step a3).
  • step a4) an alkali, in an amount sufficient for reaching pH >12, is added to the supernatant obtained in step a3) to precipitate hyaluronic acid in form of a sediment,
  • step a5) the sediment formed in step a4) is isolated and washed with 5-20mM of an alkali solution,
  • the sediment from step a5) is dissolved in acetate buffer with the concentration from 10 to 100 mM, pH between 5.5 and 6.5, and containing sodium sulfate or potassium sulfate in the concentration 100-300 mM.
  • the alkali in step a4) is selected from the group comprising NaOH, KOH, and LiOH, the concentration of the alkali is 1M, and the added volume is 20 to 40 ⁇ , per 200 to 500 ]xL of the supernatant, preferably 25 ⁇ ⁇ of 1M NaOH per 400 ⁇ , of supernatant.
  • the sediment is separated preferably by centrifugation in step a5) and is washed with 5-20mM alkali selected from the group comprising NaOH, KOH, and LiOH, more preferably it is washed at least two times with lOmM NaOH.
  • the acetate buffer in step a6) preferably has pH 6, its concentrationis lOOmM, and the sulfate is preferably Na 2 S0 4 with the concentration 160 mM.
  • the concentration C(HA) of hyaluronic acid in the sample in mg/mL is calculated in step f) preferably according to the formula: r j r & _ ⁇ A s -Ab)*V ⁇ colored sample ⁇ )*M( HA2)
  • a s is the absorbance of the sample
  • Ab is the absorbance of the background taking into account the dilution after the colour development
  • V(colored sample) is the final volume of the reaction mixture
  • ⁇ ( ⁇ 2) is the molecular weight of the unsaturated disaccharide of hyaluronic acid, 379 g/mol
  • ⁇ is the extinction coefficient, 34735 mol "1
  • V(HA sample) is the volume of the original sample in the final volume of the reaction mixture.
  • the activity of SpHyl was assayed on pure 0.1% HA, pure 0.1-2% chondroitin sulfate (CS) or on their mixes with constant 0.1% HA and 0.1-2% CS in a variety of buffers, which, however, always contained 50 mM sodium acetate buffer pH 6.
  • the activity of SpHyl was defined as an increase in samples absorbance at 232 nm referred to 1 mg of enzyme.
  • the slope of the linear part of the kinetic curve corresponded to enzyme activity according to the following formula: ⁇ 23 2 ⁇ 1000 T T r , -.
  • Activity — [U/mg ] where ⁇ 232 - absorbance difference between the sample and background at 232 nm; At - time, min; ⁇ - extinction coefficient, 5500 mol.l ⁇ .cm "1 ; C - protein concentration, mg/mL.
  • the unit of the activity is defined as the amount of enzyme necessary for the formation of one ⁇ of unsaturated bonds in 0.1%w/v HA at pH 6 at 37°C in one minute.
  • the complete protocol was prepared for the HA samples contaminated with high concentrations of sulfated glycosaminoglycans (up to 5%w/v of CS) and reducing sugars (up to 5 %w/v of glucose). It describes the most preferred conditions of the method according to the invention.
  • the process volumes were optimized for the standard spectrophotometric cell with the light path of 10 mm and volume approx. 1 mL.
  • a s and Ab are absorbances of the "sample” and “background", taking into account the dilution after the colour development;
  • V(colored sample) is the final volume of the reaction mixture, it is 1.3 mL for this protocol;
  • M(AHA2) is the molecular weight of unsaturated disaccharide, 379 g/mol;
  • ⁇ is the extinction coefficient, 34735 mol "1 ;
  • V(HA sample) is the volume of the sample in the final volume of the reaction mixture, 0.04 mL for this protocol.
  • the original protocol can be simplified, if the sample comprises small amounts of reducing sugars.
  • concentration of the reducing sugars can be considered low, if the absorbance of "background" at 654 nm is less than 0.7.
  • the absorbance of the "background” is determined as follows: mix 100 ⁇ of the sample with 100 of the solution A; add 200 ⁇ of the solution C and 400 ⁇ L of the solution D; incubate for 5 minutes at 95°C; let it cool and measure at 654 nm.
  • steps 4-7 can be skipped and 200 ⁇ ⁇ of the supernatant from step 3 are pipetted to both the "sample” and the "background” tubes, then the procedure continues from the step 8 to 12 of the complete protocol.
  • the modifications do not affect the formula; HA concentration is calculated in the same way as in the complete protocol.
  • the protocol can be simplified further.
  • concentration of sulfated glycosaminoglycans can be considered low, if the addition of 300 ⁇ of the solution B into the mixture of 100 ⁇ L of the sample and 100 ⁇ , of the solution A does not lead to the formation of a precipitate or turbidity. In that case, steps 2-3 are also omitted, besides the already omitted steps 4-7.
  • the first step changes: 200 iL of a sample is mixed with 200 of the solution A, and after vortexing the solution is divided into equal parts: the "sample" and the "background". Then the procedure continues from step 8. An increase of the volume in the first step leads to a change of the formula for HA calculation:
  • Fig. 1 represents the result of the reaction of 0.5% HA (weight average molecular weights from 24 kDa to 2049 kDa) with MBTH according to the Anthon-Barrett method.
  • the first condensation reaction was performed at 80°C for 30 min.
  • Fig. 2 represents the absorbance of the HA sample with the concentration of 0.1% after incubation with MBTH at various temperatures.
  • the optical density increases in time due to the degradation of HA in a peeling reaction.
  • Fig. 3 represents the enzymatic activity of S. pneumoniae hyaluronan lyase SpHyl.
  • Fig. 4 represents the repeatability of the presented method at various temperatures and times of the reaction.
  • HA samples were mixed with the solution A, digested with SpnHyl, then solutions C and D were added into the reaction mixture according to the protocol (see the Methods). Then the samples were subjected to heating at 73, 75, and 77°C for 30, 40, and 50 minutes. Immediately after heating, the solution E was added into the heated reaction mixture. After cooling to the room temperature and colour development, the absorbance spectra were measured in the range of 500-700 nm.
  • Fig. 5 represents the influence of the molecular weight of HA on the accuracy of the presented method.
  • the process volumes were optimized for the standard photometric cell with the light path of 10 mm and volume approx. 1 mL.
  • the process volumes were optimized for the standard photometric cell with 10 mm light path and volume of approx. 1 mL.
  • 100 ⁇ ⁇ of the analysed sample are mixed with 100 ⁇ . of the solution A (lOOmM acetate buffer of pH6, 160mM Na 2 S0 4 ) and the mixture is vortexed for 5 seconds.
  • 300 ⁇ , of the solution B (l%w/v CTAB, 50mM acetate buffer of pH6, 80mM Na 2 S0 ) are added and the mixture is vortexed again for 5 seconds.
  • the sediment is removed by centrifugation at >12000 g for 5 minutes.
  • the process volumes were optimized for the standard photometric cell with 10 mm light path and volume of approx. 1 mL.
  • the reducing sugars are often used as a component of cultivation media and veterinary and pharmaceutical preparations.
  • the use of SpnHyl-MBTH method enables determination of HA in such samples.
  • the process volumes were optimized for the standard photometric cell with 10 mm light path and volume of approx. 1 mL.
  • Sample of HA comprising sulfated glycosaminoglycans but not comprising reducing sugars
  • the process volumes were optimized for the standard photometric cell with 10 mm light path and volume of approx. 1 mL.
  • 100 ⁇ , of the analysed sample and 100 ⁇ , of the solution A (lOOmM acetate buffer of pH 6,5, 200mM Na 2 S0 4 ) are mixed and the mixture is vortexed for 5 seconds.
  • 300 ⁇ . of the solution B (l%w/v CTAB, 50mM acetate buffer pH 6, lOOmM Na 2 S0 4 ) are added and the mixture is vortexed again for 5 seconds.
  • the sediment is removed by centrifugation at >12000 g for 5 minutes.
  • the sediment (complex) is dissolved in 400 ⁇ , of the solution A, the microtube is marked as the "sample” and 200 ⁇ of the solution is pipetted into the second tube marked as the "background”.
  • 1 ih of SpnHyl enzyme 1000 U/mg, 2 mg/mL is added into the neglectsample” tube and the mixture is incubated for 15 minutes at 37°C.
  • 200 ⁇ of the solution C (1M NaOH) and 400 ⁇ , of the solution D (0.3%w/v MBTH and 5mM DTT) are added into both tubes - the "sample” and the "background". The mixture is mixed thoroughly and incubated at 95°C for 5 minutes.
  • Geloren (Contipro, a.s.) is a gelatine gel tablet for dogs and horses.
  • the "dog” version comprises 0.6% HA, 5% CS, 1.24% glucosamine, 7% hydrolysed collagen, 28% gelatine (http-V/wwvv ⁇ educationnizvirexz/kloubni-vyziva-pro-psy).
  • the "horse” version comprises 0.4% HA, 1.9% CS, 15.5%> gelatine, and also a high amount of glucose (http://www.2011nizvire.cz vyziva-kloubu-kone). All percents indicated in the Geloren composition are weight percents, i.e. w/w.
  • a slice of gel of the size of approx. 0.1 g was weighed and then melted in 9 volumes of 20mM Tris-HCl buffer pH 8 at 80°C. Then the sample was digested with pancreatin (10 mg of pancreatin per 1 mL of the melted gel) at 37°C for 1 hour. The digestion with pancreatin is necessary as the gelatine creates complexes with CTAB and thus inhibits the analysis (Ji et al., 2004), Then the sample is processed according to the Complete Protocol SpnHyl-MBTH including the removal of reducing sugars and CS. The measured concentration of HA was 0.408%> and 0.59% of HA for the horse and the dog version of Geloren, respectively.
  • the MBTH-SpHyl method was used for the monitoring of HA content during the whole manufacturing process beginning from Streptococcus zooepidermicus (SEZ) cultivation, through to the downstream processes and ending with the final product. More than 500 samples were analyzed in total.
  • Haserodt S, Aytekin M, Dweik RA, (201 1) A comparison of the sensitivity, specificity, and molecular weight accuracy of three different commercially available Hyaluronan ELISA-like assays. Glycobiology 21(2):175-83. doi: 10.1093/glycob/cwql45.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de détermination de la présence d'acide hyaluronique dans des échantillons complexes par clivage à l'aide de l'enzyme SpnHyl, puis réaction avec de la 3-méthyl-2-benzothiazolinone hydrazone (MBTH) pour former un produit coloré analysé par spectrophotométrie. Dans le cas d'une teneur élevée en glycosaminoglycanes, ceux-ci peuvent être séparés par précipitation avant le clivage, par exemple en utilisant du bromure de cétyltriméthylammonium (CTAB) dans un tampon acétate et un milieu salin. Dans le cas d'une teneur élevée en sucres réducteurs, par exemple le glucose, leur influence peut être éliminée, après élimination des glycosaminoglycanes et avant le clivage, par précipitation de l'acide hyaluronique hors du surnageant formé, puis re-dissolution de ce sédiment dans du tampon acétate et mise en œuvre de l'étape de clivage.
EP18722381.3A 2017-03-16 2018-03-15 Procédé de détermination de la présence d'acide hyaluronique Withdrawn EP3596224A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2017145 2017-03-16
PCT/CZ2018/050009 WO2018166545A1 (fr) 2017-03-16 2018-03-15 Procédé de détermination de la présence d'acide hyaluronique

Publications (1)

Publication Number Publication Date
EP3596224A1 true EP3596224A1 (fr) 2020-01-22

Family

ID=62116153

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18722381.3A Withdrawn EP3596224A1 (fr) 2017-03-16 2018-03-15 Procédé de détermination de la présence d'acide hyaluronique

Country Status (2)

Country Link
EP (1) EP3596224A1 (fr)
WO (1) WO2018166545A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112945946B (zh) * 2021-01-27 2022-10-04 青岛琛蓝海洋生物工程有限公司 一种测定透明质酸凝胶体外酶降解率的方法
CN114457061A (zh) * 2022-02-21 2022-05-10 中国海洋大学 一种透明质酸裂解酶及其应用
CN114894789B (zh) * 2022-06-28 2025-08-15 华熙生物科技股份有限公司 一种透明质酸类物质指示剂组合物及其在快速检测透明质酸类物质中的应用
CN115856152B (zh) * 2022-12-28 2025-02-14 天津键凯科技有限公司 一种动物血浆中透明质酸钠凝胶代谢时间的检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304140B6 (cs) * 2012-09-27 2013-11-13 Contipro Biotech S.R.O. Enzym hyaluronan-lyáza, zpusob jeho výroby, pouzití a zpusob prípravy nízkomolekulárního hyaluronanu

Also Published As

Publication number Publication date
WO2018166545A1 (fr) 2018-09-20

Similar Documents

Publication Publication Date Title
Pepeliaev et al. Colorimetric enzyme-coupled assay for hyaluronic acid determination in complex samples
WO2018166545A1 (fr) Procédé de détermination de la présence d'acide hyaluronique
Spiro [1] Analysis of sugars found in glycoproteins
Rosenberg et al. Purification and chemical properties of Acinetobacter calcoaceticus A2 biodispersan
Muckenschnabel et al. Quantitation of hyaluronidases by the Morgan–Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers
Chen et al. Preparation, chemical structure and α-glucosidase inhibitory activity of sulfated polysaccharide from Grifola frondosa
Prado et al. A simple and sensitive method for determining reducing sugars in plant tissues. Application to quantify the sugar content in quinoa (Chenopodium quinoa Willd.) seedlings
EP3279220B1 (fr) Procédé de sulfatation de glycosaminoglycane
CN111443149A (zh) 测定注射用透明质酸钠复合溶液中盐酸赖氨酸含量的方法
EP1021463B1 (fr) Lysates des amebocytes reduits en quantite de facteur g pour detecter des endotoxines bacteriennes
JP5466405B2 (ja) ヒアルロン酸の分子量の測定方法
Estevinho et al. Uncertainty in the determination of glucose and sucrose in solutions with chitosan by enzymatic methods
JP2000002708A (ja) エンドトキシン特異的アッセイ
Zhang et al. Glycosaminoglycan quality control by monosaccharide analysis
Sun et al. An enzyme-pHBH method for specific quantification of porphyran
Tian et al. Quantitative determination of chondroitin sulfate with various molecular weights in raw materials by pre-column derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate
Bailey et al. Optimization of the USP assay for hyaluronidase
Zhang et al. PCR instrument-assisted acidolysis for monosaccharide composition analysis of serum glycans
LeBrun et al. Degradation of heparan sulfate with heparin lyases
EP0005867B1 (fr) Détermination de l'alpha-amylase, une composition réactive et une système réactive pour ladite détermination
JP2688773B2 (ja) エンドトキシンの不活化方法
JP2021116271A (ja) キトサンオリゴ糖の分取方法
RU2017819C1 (ru) СПОСОБ КОЛИЧЕСТВЕННОГО ОПРЕДЕЛЕНИЯ 1,3- β -ГЛЮКАНОВ
Boros et al. USE OF NINHYDRIN REACTION FOR ESTIMATION OF ACETYLATION DEGREE OF CHITOSAN.
JPH0394697A (ja) キチン、キトサンの脱アセチル化度の測定法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220604